Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zohydro
- Development stage
- Approved
- Lead developer
- Tabros
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Zohydro** is a Tabros topical fixed-dose cream containing clotrimazole 1% and hydrocortisone 1%. Clotrimazole is an imidazole antifungal that disrupts fungal ergosterol biosynthesis, while hydrocortisone is a low-potency glucocorticoid that reduces local inflammation, erythema, and pruritus. The product is marketed as a 10 g cream for fungal skin infections accompanied by inflammatory symptoms. ([multanpluspharmacy.com](https://multanpluspharmacy.com/products/zohydro-cream-10g))
- Brand names
- Zohydro
- Other names
- Zohydro Cream
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)GR (Glucocorticoid receptor)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on Zohydro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zohydro.